Merck
CN
  • Increased cerebrovascular sensitivity to endothelin-1 in a rat model of obstructive sleep apnea: a role for endothelin receptor B.

Increased cerebrovascular sensitivity to endothelin-1 in a rat model of obstructive sleep apnea: a role for endothelin receptor B.

Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism (2014-11-27)
David J Durgan, Randy F Crossland, Eric E Lloyd, Sharon C Phillips, Robert M Bryan
ABSTRACT

Obstructive sleep apnea (OSA) is associated with cerebrovascular diseases. However, little is known regarding the effects of OSA on the cerebrovascular wall. We tested the hypothesis that OSA augments endothelin-1 (ET-1) constrictions of cerebral arteries. Repeated apneas (30 or 60 per hour) were produced in rats during the sleep cycle (8 hours) by remotely inflating a balloon implanted in the trachea. Four weeks of apneas produced a 23-fold increase in ET-1 sensitivity in isolated and pressurized posterior cerebral arteries (PCAs) compared with PCAs from sham-operated rats (EC50=10(-9.2) mol/L versus 10(-10.6) mol/L; P<0.001). This increased sensitivity was abolished by the ET-B receptor antagonist, BQ-788. Constrictions to the ET-B receptor agonist, IRL-1620, were greater in PCAs from rats after 2 or 4 weeks of apneas compared with that from sham-operated rats (P=0.013). Increased IRL-1620 constrictions in PCAs from OSA rats were normalized with the transient receptor potential channel (TRPC) blocker, SKF96365, or the Rho kinase (ROCK) inhibitor, Y27632. These data show that OSA increases the sensitivity of PCAs to ET-1 through enhanced ET-B activity, and enhanced activity of TRPCs and ROCK. We conclude that enhanced ET-1 signaling is part of a pathologic mechanism associated with adverse cerebrovascular outcomes of OSA.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Anti-TRPC1 antibody produced in rabbit, affinity isolated antibody, lyophilized powder
Sigma-Aldrich
BQ-788, ≥95%, solid
Enrofloxacin for system suitability, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
DL-Glyceraldehyde 3-phosphate solution, 45-55 mg/mL in H2O
Sigma-Aldrich
DAPI, for nucleic acid staining
Sigma-Aldrich
Anti-phospho-MYPT1 (Thr696) Antibody, from rabbit, purified by affinity chromatography
Sigma-Aldrich
Ketoprofen, meets USP testing specifications
Sigma-Aldrich
Anti-TRPC3 antibody produced in rabbit, affinity isolated antibody, lyophilized powder
Sigma-Aldrich
Ketoprofen, ≥98% (TLC)
Sigma-Aldrich
BQ-123, ≥99%, sodium salt, lyophilized powder
Sigma-Aldrich
Enrofloxacin, ≥99.0%
Ketoprofen, European Pharmacopoeia (EP) Reference Standard
Supelco
Ketoprofen, VETRANAL®, analytical standard
Enrofloxacin, European Pharmacopoeia (EP) Reference Standard
Supelco
Enrofloxacin, VETRANAL®, analytical standard
USP
Enrofloxacin, United States Pharmacopeia (USP) Reference Standard
Supelco
Ketoprofen, Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
Enrofloxacin, Pharmaceutical Secondary Standard; Certified Reference Material
USP
Ketoprofen, United States Pharmacopeia (USP) Reference Standard